Vahid Osman
Psychiatry · Indianapolis, INNPI 1740264720
Payments from drug & device makers
Across 274 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$543
- Johnson & Johnson$517
- Vanda Pharmaceuticals Inc.$406
- Takeda Pharmaceuticals U.S.A., Inc.$405
- Adlon Therapeutics L.p.$336
- Neurocrine Biosciences, Inc.$263
- plus $2K from 19 others
What the payments were for
- Food & beverage$4,38697%
- Education$1433%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 45 | $543 |
| Johnson & Johnson | 41 | $517 |
| Vanda Pharmaceuticals Inc. | 18 | $406 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $405 |
| Adlon Therapeutics L.p. | 21 | $336 |
| Neurocrine Biosciences, Inc. | 17 | $263 |
| Otsuka America Pharmaceutical, Inc. | 13 | $263 |
| Teva Pharmaceuticals USA, Inc. | 10 | $239 |
| Lundbeck LLC | 12 | $220 |
| Sunovion Pharmaceuticals Inc. | 13 | $208 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $202 |
| Eisai Inc. | 9 | $197 |
| Supernus Pharmaceuticals, Inc. | 6 | $91 |
| Ironshore Pharmaceuticals Inc. | 5 | $91 |
| Indivior Inc. | 6 | $91 |
| Neos Therapeutics, LP | 5 | $86 |
| Jazz Pharmaceuticals Inc. | 5 | $80 |
| Alkermes, Inc. | 5 | $78 |
| Shire North American Group Inc | 3 | $57 |
| Corium, LLC | 3 | $47 |
| Brainsway USA Inc | 1 | $40 |
| Bausch Health US, LLC | 2 | $34 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Orexo US, Inc. | 1 | $13 |
| Neuronetics, Inc. | 1 | $10 |
How this compares
$4,530 in reported general payments places this provider in the 85th percentile of 514 psychiatry providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 53 | $44,990 |
| ProzacFluoxetine Hcl | 39 | $24,991 |
| Aripiprazole | 113 | $16,820 |
| Risperdal ConstaRisperidone Microspheres | 12 | $15,251 |
| Buspirone Hcl | 221 | $7,800 |
| Quetiapine Fumarate | 246 | $7,444 |
| Risperidone | 316 | $4,446 |
| Guanfacine Hcl ErGuanfacine Hcl | 37 | $3,685 |
| Clozapine | 14 | $3,222 |
| Fluvoxamine Maleate | 66 | $3,038 |
| Divalproex Sodium ErDivalproex Sodium | 46 | $2,742 |
| Olanzapine | 101 | $2,684 |
| Fluoxetine Hcl | 280 | $2,626 |
| Naltrexone Hcl | 14 | $2,332 |
| Lithium Carbonate | 185 | $1,905 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonRisperdal Consta | $517 | $15,25112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in Indianapolis
- Anantha ShekharIndianapolis$433K
- Leslie HulvershornIndianapolis$159K
- Charles BeasleyIndianapolis$129K
- Alan BreierIndianapolis$114K
- John NurnbergerIndianapolis$104K
- Susan ConroyIndianapolis$73K
- Dmitry ArbuckIndianapolis$40K
- Michael FrancisIndianapolis$26K
- Albert AllenIndianapolis$24K
- Jerad DaltonIndianapolis$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.